Please ensure Javascript is enabled for purposes of website accessibility

Is GoodRx the Prescription for Your Portfolio?

By Steve Ditto - Updated Jun 15, 2021 at 7:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

You're probably paying too much for your drugs. Fortunately, there's some help on the way.

Americans spend about $1,200 per person per year on prescription drugs -- more than anywhere else in the world. Unlike other countries, the U.S. doesn't directly regulate medicine prices. As with many areas of the healthcare system, saving money in the $359 billion prescription drug market can be a tall order.

GoodRx (GDRX -1.40%) was founded to address this high-cost problem and "help Americans get the healthcare they need at a price they can afford." Does its potential to disrupt make it a good fit for your portfolio?

Pharmacist helps a senior at the pharmacy counter.

Image source: Getty Images.

The complicated world of prescription drugs

The prescription drug buying process seems deceptively straightforward: Go to the doctor, get a prescription, pick it up at your local pharmacy. But under the surface, the market is quite complex and filled with middlemen all trying to make a profit -- which often comes at the expense of the consumers they purport to serve.

Drug companies sell to wholesalers, who then sell to pharmacies. Pharmacy benefit managers (PBMs) negotiate prices for health insurance companies. Health insurance companies then develop formularies, which are essentially price lists for their members, to encourage the use of certain drugs (e.g., generics) or delivery methods (e.g., 90-day supply via mail order).

Drug pricing gets increasingly complex as each of these players negotiates prices, fees, discounts, rebates, and incentives. Industry studies have criticized PBM contracts for their "complexity and opaqueness with multiple, hard to track, sources of revenue." The effect on consumer pricing is made even more complex by the level of government involvement in Medicare and Medicaid markets.

The high cost of complexity comes out of your pocket

Unlike almost anything else you would buy in your local grocery store, drug pricing can vary widely. For example, Crestor from AstraZeneca (AZN 0.12%) is one of the most commonly prescribed medications for high cholesterol. It's now available in generic form as rosuvastatin. If you visited the pharmacies in your local area to fill a 30-day supply of the generic version, you might find prices ranging from $10 to $80.  

For many consumers, it's probably hard to believe there could be an 8x price difference for the same drug from nearby pharmacies. It may be even harder to believe someone could "walk in off the street" and pay less than the rate negotiated by their expensive health insurance company and its PBM partners. That's where GoodRx comes in.

How do we fix this mess?

Instead of trying to address the problem through legislation or negotiation, GoodRx created a third-party marketplace where pricing is transparent and everyone competes to provide the best deal to consumers.

When you open the GoodRx app and type in a drug name, you immediately see all the pricing from local pharmacies. These pharmacies are incentivized to reduce prices to capture customers and generate store traffic. The wholesalers and PBMs are incentivized to reduce their prices to help win the business. The big winners are the consumers, who have choice, transparency, and the best available drug price. For its troubles, GoodRx takes a cut (yes another middleman, but at least one with a consumer-centric focus). 

Unlike many young tech companies, GoodRx is profitable with high gross margins in the mid-90s and operating margins in the mid-30s. In the first quarter, monthly active consumers were up 17% and prescription transaction revenue increased by 9% year over year. In a good sign of things to come, GoodRx saw revenue from other sources, including telehealth and drug manufacturer programs, increase by 154% to $26.4 million. These new programs will be critical to increasing consumer stickiness and creating value beyond low prices.

What can go wrong?

Since its Q1 earnings call, GoodRx has declined more than 40% from its 52-week high. Unlike some other companies, it's not because GoodRx was a COVID stock falling in a reopening stock rotation. Two things seem to be weighing on the minds of investors. 

First, Amazon (AMZN 0.14%) announced the first enterprise client for its new Amazon Care services. Amazon is moving into healthcare, and prescription drugs are a particular area of focus. You can't easily discount potential competition from Amazon since price transparency between competing merchants is one of the core functions of the Amazon Marketplace.

Second, as part of its recent IPO, GoodRx issued a "Founders Award" of $533 million in equity to its co-CEOs. Although this type of stock compensation is fairly typical, the awards weren't mentioned in the initial IPO prospectus and the amount is considered higher than normal. Management has positioned the award as a one-time event, but if overly generous stock awards are repeated it would be detrimental to other shareholders and bears watching.

If you're like the half of all Americans who will need to fill your prescription this month, then by all means check out GoodRx. Your pocketbook will likely be the beneficiary of newly found market competition. If you're an investor, keep an eye on GoodRx to see how the potential competition and compensation issues play out for this industry disruptor.

Steve Ditto owns shares of GoodRx. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. The Motley Fool owns shares of and recommends Amazon. The Motley Fool recommends GoodRx Holdings, Inc. and recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GoodRx Holdings, Inc. Stock Quote
GoodRx Holdings, Inc.
GDRX
$6.35 (-1.40%) $0.09
Amazon.com, Inc. Stock Quote
Amazon.com, Inc.
AMZN
$142.30 (0.14%) $0.20
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.50 (0.12%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.